RAPT Therapeutics is leveraging advanced liquid handling technologies to accelerate the development of small molecule therapies for cancer and inflammatory diseases. The company's research and development team utilizes INTEGRA Biosciences' liquid handling solutions to efficiently analyze drug candidates at every stage, from initial discovery to clinical trials.
Streamlining Drug Candidate Analysis
Steven Lomeli Gonzalez, a research associate in RAPT Therapeutics' Immunology Department, highlighted the impact of INTEGRA's tools. "I work with EVOLVE manual pipettes and VIAFLO 96 electronic pipettes on a day-to-day basis, and find their performance outstanding," he noted. The VIAFLO 96 pipette has been particularly beneficial for enhancing productivity, allowing the team to dispense entire 96-well plates in a single step.
Impact on Clinical Trial Progression
The enhanced efficiency gained through these technologies directly contributes to the advancement of RAPT's small molecule inhibitors through clinical trials. "With our efficient, ergonomic and accurate pipettes, we can continue to progress our small molecule inhibitors through clinical trials to improve cancer and autoimmune disease treatment," Gonzalez stated. RAPT Therapeutics currently has two promising drug candidates in clinical trials.
Focus on Immunology and Small Molecule Therapies
RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology-based small molecule therapies. The company's immunology laboratory employs INTEGRA pipettes to develop and execute assays that characterize immune cell subsets following disease onset and drug administration. These assays provide critical insights before and after clinical trials, informing the development of innovative therapies.
